

| 货号 | PTX20581 |
|---|---|
| 品牌 | ProteoGenix |
| 描述 |
Anti-Mouse CD22 Polyclonal Antibody (PTX20581) is a rabbit polyclonal antibody detecting B-cell receptor CD22 (B-lymphocyte cell adhesion molecule) (BL-CAM) (Sialic acid-binding Ig-like lectin 2) (Siglec-2) (T-cell surface antigen Leu-14) (CD antigen CD22) in ELISA, IHC, WB. Suitable for Mouse.
Highlights
|
| 种属反应性 | Mouse |
| 应用 | ELISA, IHC, WB |
| 宿主 | Rabbit |
| 同种型 | IgG |
| 克隆类型 | Polyclonal |
| 免疫原 | E. coli - derived recombinant Mouse CD22 (Val146-Glu343). |
| 靶标 | B-cell receptor CD22 (B-lymphocyte cell adhesion molecule) (BL-CAM) (Sialic acid-binding Ig-like lectin 2) (Siglec-2) (T-cell surface antigen Leu-14) (CD antigen CD22) |
| 纯化方式 | Purified by antigen affinity column. |
| Accession号 | P35329 |
| 状态 | Liquid |
| 保存溶液 | 0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA. |
| 稳定性和存储 | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| 背景 | B-cell receptor CD22 is a ~97 kDa protein. Most highly expressed siglec (sialic acid-binding immunoglobulin-like lectin) on B-cells that plays a role in various aspects of B-cell biology including differentiation, antigen presentation, and trafficking to bone marrow. Binds to alpha 2,6-linked sialic acid residues of surface molecules such as CD22 itself, CD45 and IgM in a cis configuration. Can also bind to ligands on other cells as an adhesion molecule in a trans configuration. Acts as an inhibitory coreceptor on the surface of B-cells and inhibits B-cell receptor induced signaling, characterized by inhibition of the calcium mobilization and cellular activation. Mechanistically, the immunoreceptor tyrosine-based inhibitory motif domain is phosphorylated by the Src kinase LYN, which in turn leads to the recruitment of the protein tyrosine phosphatase 1/PTPN6, leading to the negative regulation of BCR signaling. CD22 is the therapeutic target of inotuzumab ozogamicin (Besponsa). 1. Kelm, S. et al. (1994) Current biology : CB 4, 965-72. PMID: 7533044 2. Nitschke, L. et al. (1997) Current biology : CB 7, 133-43. PMID: 9016707 |
| Note | For research use only. |

24小时产品查询

扫一扫关注我们

专属渠道经理